Item 2.
Properties.
BD’s executive offices are located in Franklin Lakes, New Jersey.
As of October 31, 2017, BD owned or leased 289 facilities throughout the world, comprising approximately 20,462,405 square feet of manufacturing, warehousing, administrative and research facilities.
The U. S.  facilities, including those in Puerto Rico, comprise approximately 7,472,419 square feet of owned and 2,976,267 square feet of leased space.
The international facilities comprise approximately 7,478,714 square feet of owned and 2,535,005 square feet of leased space.
Sales offices and distribution centers included in the total square footage are also located throughout the world.
Operations in each of BD’s business segments are conducted at both U. S.  and international locations.
Particularly in the international marketplace, facilities often serve more than one business segment and are used for multiple purposes, such as administrative/sales, manufacturing and/or warehousing/distribution.
BD generally seeks to own its manufacturing facilities, although some are leased.
The following table summarizes property information by business segment.
## Table 0 ##
(A) Facilities used by more than one business segment.
BD believes that its facilities are of good construction and in good physical condition, are suitable and adequate for the operations conducted at those facilities, and are, with minor exceptions, fully utilized and operating at normal capacity.
The U. S.  facilities are located in Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Maryland, Massachusetts, Michigan, Missouri, Nebraska, New Jersey, North Carolina, Ohio, Oklahoma, South Carolina, Texas, Utah, Virginia, Washington, D. C. , Washington, Wisconsin and Puerto Rico.
The international facilities are as follows: - Europe, Middle East, Africa, which includes facilities in Austria, Belgium, Bosnia and Herzegovina, the Czech Republic, Denmark, England, Finland, France, Germany, Ghana, Hungary, Ireland, Israel, Italy, Kenya, Luxembourg, Netherlands, Norway, Poland, Portugal, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, the United Arab Emirates and Zambia.
- Greater Asia, which includes facilities in Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, New Zealand, the Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam.
- Latin America, which includes facilities in Argentina, Brazil, Chile, Colombia, Mexico, Peru and the Dominican Republic.
- Canada.
Item 3.
Legal Proceedings.
Information with respect to certain legal proceedings is included in Note 5 to the consolidated financial statements contained in Item 8.
Financial Statements and Supplementary Data, and is incorporated herein by reference.
Item 4.
Mine Safety Disclosures.
Not applicable.
Selling and Administrative (S&A) S&A, as a percentage of sales, decreased 120 bps to 15.9% versus 17.1%.
The 2011 amount includes $33.5 million related to the Mane patent litigation settlement.
Excluding this amount, S&A would have declined 240 bps to 14.7% of sales.
The decrease in S&A expenses was driven by lower provisions for incentive compensation and ongoing cost discipline that more than offset planned spend in sales activities (mainly in emerging markets) to support our growth initiatives.
Restructuring and Other Charges
## Table 1 ##
Strategic Initiative In December 2011, we recorded a charge to cover a restructuring which involved a reduction in workforce as well as a realignment of responsibilities in our Fragrances business unit.
This alignment partly addresses issues identified in our 2010 strategic review process towards improving the underperforming areas of our portfolio.
It will result in the redeployment of creative resources in emerging markets and the reorganization from a regional to a global category structure.
We implemented a plan to streamline business operations globally which resulted in the elimination of 72 positions, across Fragrances, Flavors and Corporate functions.
As a result, we recorded a provision for severance costs of $9.8 million to Restructuring and other charges, net in our 2011 Consolidated Statement of Income and Comprehensive Income.
European Rationalization Plan During the second quarter 2011, we executed a partial settlement of its pension obligations with the former employees of the Drogheda, Ireland facility.
As a result we recorded a charge of $3.9 million related to the European Rationalization Plan to cover settlements and special termination benefits.
This settlement was funded primarily through pension plan investment trust assets.
We also reversed $1.2 million of employee-related liabilities in 2011 due to certain employees accepting other roles within the Company, offset by $0.6 million of additional costs incurred.
Based upon the period-end estimates regarding the separation agreements, we increased our provision for severance costs in by $4.4 million in 2010.
The remaining $5.7 million of the restructuring charges in 2010 was mainly due to accelerated depreciation and other restructuring related costs pertaining to the rationalization of our Fragrances and Ingredients operations in Europe.
In the aggregate as of December 31, 2011, we have recorded expenses of $34.1 million relating to the European Rationalization Plan and $9.8 million for the Strategic Initiative, of which $37.6 million was recorded to Restructuring and other charges, net and $6.3 million recorded to Cost of goods sold, R&D and Selling and administrative expenses.
We do not anticipate any further expenses related to the European Rationalization Plan.
Operating Results by Business Unit We evaluate the performance of business units based on profit before Restructuring and other charges, net, Interest expense, Other expense, net and Taxes on income.
See Note 12 to our Consolidated Financial Statements for the reconciliation to Income before taxes.
The deferred tax assets consist of the following amounts:
## Table 2 ##
(1) During 2012, the Company increased its deferred tax assets by $129 million.
The 2012 amount includes a revision to the 2011 foreign net operating loss carryforwards in the amount of $74 million and a $55 million increase related to current year internally generated intangible assets.
The revision is not considered material to the previously issued financial statements.
This entire increase of $129 million was offset by a corresponding increase in valuation allowances.
Net operating loss carryforwards were $273 million and $175 million at December 31, 2012 and 2011, respectively.
If unused, $6 million will expire between 2013 and 2032.
The remainder, totaling $267 million, may be carried forward indefinitely.
Tax credit carryforwards were $36 million at December 31, 2012 and 2011.
If unused, the credit carryforwards will expire between 2013 and 2031.
The U. S.  consolidated group has historically generated taxable income after the inclusion of foreign dividends.
As such, the Company is not in a federal net operating loss position.
This allows IFF and its U. S.  subsidiaries to realize tax benefits from the reversal of temporary differences and the utilization of its federal tax credits before the expiration of the applicable carryforward periods.
The Company has not factored any future trends, other than inflation, in its U. S.  taxable income projections.
The corresponding U. S.  federal taxable income is sufficient to realize $187.2 million in deferred tax assets as of December 31, 2012.
The majority of states in the U. S.  where IFF and its subsidiaries file income tax returns allow a 100% foreign dividend exclusion, effectively converting the domestic companies’ reversing temporary differences into net operating losses.
As there is significant doubt with respect to realizability of these net operating losses, we have established a full valuation allowance against these deferred tax assets.
Of the $309 million deferred tax asset for net operating loss carryforwards and credits at December 31, 2012, we consider it unlikely that a portion of the tax benefit will be realized.
Accordingly, a valuation allowance of $268 million of net operating loss carryforwards and $9 million of tax credits has been established against these deferred tax assets, respectively.
In addition, due to realizability concerns, we established a valuation allowance against certain other net deferred tax assets of $174 million.
premiums based on benefits paid.
We do not generally provide health care or life insurance coverage for retired employees of foreign subsidiaries; such benefits are provided in most foreign countries by government-sponsored plans, and the cost of these programs is not significant to us.
We offer a non-qualified Deferred Compensation Plan (DCP) for certain key employees and non-employee directors.
Eligible employees and non-employee directors may elect to defer receipt of salary, incentive payments and Board of Directors’ fees into participant directed investments, which are generally invested by the Company in individual variable life insurance contracts we own that are designed to informally fund savings plans of this nature.
The cash surrender value of life insurance is based on the net asset values of the underlying funds available to plan participants.
At December 31, 2012 and December 31, 2011, the Consolidated Balance Sheet reflects liabilities of $27.0 million, for both years, related to the DCP in Other liabilities and $12.3 million and $12.0 million, respectively, included in Capital in excess of par value related to the portion of the DCP that will be paid out in IFF shares.
The total cash surrender value of life insurance contracts the Company owns in relation to the DCP and post-retirement life insurance benefits amounted to $51.3 million and $56.2 million at December 31, 2012 and 2011, respectively, and are recorded in Other assets in the Consolidated Balance Sheet.
The plan assets and benefit obligations of our defined benefit pension plans are measured at December 31 of each year.
## Table 3 ##
During the second quarter 2011, we settled a portion of the Ireland pension plan as discussed in Note 2.
As a result, we recorded a settlement charge and a special termination benefit charge of $3.9 million to recognize a portion of the unrecognized loss related to those employees who have accepted the settlement and for additional benefits credited to those participants accepting a settlement.
This settlement was funded primarily through pension plan investment trust assets.

<table><tr><td>Sites</td><td>Corporate</td><td>BD Life Sciences</td><td>BD Medical</td><td>Mixed(A)</td><td>Total</td></tr><tr><td>Leased</td><td>14</td><td>25</td><td>96</td><td>83</td><td>218</td></tr><tr><td>Owned</td><td>6</td><td>26</td><td>33</td><td>6</td><td>71</td></tr><tr><td>Total</td><td>20</td><td>51</td><td>129</td><td>89</td><td>289</td></tr><tr><td>Square feet</td><td>2,263,694</td><td>4,421,732</td><td>10,838,632</td><td>2,938,347</td><td>20,462,405</td></tr></table>
<table><tr><td></td><td colspan="2"> Restructuring Charges  <i>( In Thousands)</i></td><td colspan="2">Positions Affected</td></tr><tr><td></td><td> 2011</td><td> 2010</td><td> 2011</td><td>2010</td></tr><tr><td>Flavors</td><td>$1,475</td><td>—</td><td>14</td><td>0</td></tr><tr><td>Fragrances</td><td>11,224</td><td>10,077</td><td>54</td><td>-10</td></tr><tr><td>Global</td><td>473</td><td>—</td><td>4</td><td>0</td></tr><tr><td>Total</td><td>$13,172</td><td>$10,077</td><td>72</td><td>-10</td></tr></table>
<table><tr><td></td><td colspan="2">December 31,</td></tr><tr><td><i>(DOLLARS IN THOUSANDS)</i></td><td>2012</td><td>2011</td></tr><tr><td> ASSETS</td><td></td><td></td></tr><tr><td>Employee and retiree benefits</td><td>$156,399</td><td>$132,210</td></tr><tr><td>Credit and net operating loss carryforwards<sup>-1</sup></td><td>308,900</td><td>210,886</td></tr><tr><td>Property, plant and equipment, net</td><td>2,643</td><td>5,015</td></tr><tr><td>Trademarks and other<sup>-1</sup></td><td>141,248</td><td>87,911</td></tr><tr><td>Amortizable R&D expenses</td><td>30,590</td><td>23,571</td></tr><tr><td>Other, net</td><td>25,148</td><td>18,729</td></tr><tr><td>Gross deferred tax assets</td><td>664,928</td><td>478,322</td></tr><tr><td>Valuation allowance<sup>-1</sup></td><td>-450,733</td><td>-290,879</td></tr><tr><td>Total net deferred tax assets</td><td>$214,195</td><td>$187,443</td></tr></table>
<table><tr><td></td><td colspan="3">U.S. Plans</td><td colspan="3">Non-U.S. Plans</td></tr><tr><td><i>(DOLLARS IN THOUSANDS)</i></td><td>2012</td><td>2011</td><td>2010</td><td>2012</td><td>2011</td><td>2010</td></tr><tr><td> Components of net periodic benefit cost</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Service cost for benefits earned</td><td>$3,121</td><td>$3,602</td><td>$3,781</td><td>$12,585</td><td>$10,560</td><td>$9,804</td></tr><tr><td>Interest cost on projected benefit obligation</td><td>24,314</td><td>24,373</td><td>24,191</td><td>30,944</td><td>34,033</td><td>32,954</td></tr><tr><td>Expected return on plan assets</td><td>-24,329</td><td>-25,070</td><td>-24,146</td><td>-43,728</td><td>-45,386</td><td>-41,569</td></tr><tr><td>Net amortization and deferrals</td><td>20,180</td><td>11,888</td><td>7,441</td><td>6,443</td><td>5,360</td><td>5,214</td></tr><tr><td>Settlement and curtailment</td><td>—</td><td>444</td><td>—</td><td>873</td><td>3,139</td><td>182</td></tr><tr><td>Special termination benefits</td><td>—</td><td>—</td><td>—</td><td>—</td><td>738</td><td>178</td></tr><tr><td>Net periodic benefit cost</td><td>23,286</td><td>15,237</td><td>11,267</td><td>7,117</td><td>8,444</td><td>6,763</td></tr><tr><td>Defined contribution and other retirement plans</td><td>7,039</td><td>6,550</td><td>7,169</td><td>4,837</td><td>4,113</td><td>4,459</td></tr><tr><td>Total expense</td><td>$30,325</td><td>$21,787</td><td>$18,436</td><td>$11,954</td><td>$12,557</td><td>$11,222</td></tr><tr><td> Changes in plan assets and benefit obligations recognized in OCI</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Net actuarial loss</td><td>$32,569</td><td>$77,924</td><td></td><td>$53,469</td><td>$32,218</td><td></td></tr><tr><td>Recognized actuarial loss</td><td>-19,810</td><td>-11,441</td><td></td><td>-7,181</td><td>-8,352</td><td></td></tr><tr><td>Prior service cost</td><td>-370</td><td>-891</td><td></td><td>—</td><td>-191</td><td></td></tr><tr><td>Recognized prior service cost</td><td>—</td><td>—</td><td></td><td>-135</td><td>-147</td><td></td></tr><tr><td>Currency translation adjustment</td><td>—</td><td>—</td><td></td><td>6,068</td><td>355</td><td></td></tr><tr><td>Total recognized in OCI (before tax effects)</td><td>$12,389</td><td>$65,592</td><td></td><td>$52,221</td><td>$23,883</td><td></td></tr></table>

Question: What's the average of Square feet of BD Life Sciences, and Net amortization and deferrals of U.S. Plans 2011 ?
Answer: 2216810.0